Pharmacokinetics of the disialoganglioside, GD2, a circulating tumor biomarker for neuroblastoma, in nonhuman primates
Open Access
- 3 December 2021
- journal article
- Published by Aboutscience Srl in Journal of Circulating Biomarkers
- Vol. 10, 26-29
- https://doi.org/10.33393/jcb.2021.2329
Abstract
Background: The ganglioside GD2 is a potential circulating tumor biomarker for the childhood cancer, neuroblastoma. Interpreting the levels of a circulating tumor biomarker depends in part on a knowledge of the biomarker’s clinical pharmacology. Background: The ganglioside GD2 is a potential circulating tumor biomarker for the childhood cancer neuroblastoma. Interpreting the levels of a circulating tumor biomarker depends in part on a knowledge of the biomarker’s clinical pharmacology. Methods: We studied the plasma and cerebrospinal fluid (CSF) pharmacokinetics of the C18 lipoform of GD2 in two nonhuman primates with indwelling subcutaneous CSF lateral ventricular reservoir systems. GD2 was quantified with a validated high-performance liquid chromatography (HPLC)/tandem mass spectrometry assay. GD2 was administered as a short intravenous infusion and frequent plasma and CSF samples were drawn over 72 hours. Results: GD2 plasma concentration declined monoexponentially with a half-life of 16 hours. Clearance was 0.0136 and 0.0131 L/h and volume of distribution (Vd) was 0.035 and 0.038 L/kg in the two animals. Vd was equivalent to plasma volume. Greater than 98% of GD2 in plasma is in a bound form consistent with its known association with lipoproteins and accounting for its limited volume of distribution. GD2 did not cross over from plasma into the CSF. Conclusions: The pharmacokinetic profile of GD2 is favorable for a circulating tumor biomarker. This study demonstrates the value of characterizing the clinical pharmacology of circulating biomarkers to better understand their clinical behavior.Keywords
This publication has 7 references indexed in Scilit:
- The ganglioside GD2 as a circulating tumor biomarker for neuroblastomaPediatric Blood & Cancer, 2019
- A validated HPLC-MS/MS method for estimating the concentration of the ganglioside, GD2, in human plasma or serumJournal of Chromatography B, 2018
- PHRM-04. COMPARISON OF PHARMACOKINETIC PARAMETERS BETWEEN NON-HUMAN PRIMATES AND HUMAN PATIENTSNeuro-Oncology, 2018
- Measurement of Blood Volume in Adult Rhesus Macaques (Macaca mulatta).2015
- Development of a cerebrospinal fluid lateral reservoir model in rhesus monkeys (Macaca mulatta).2015
- Localization of shed human tumor gangliosides: association with serum lipoproteins.1992
- Shedding of GD2 ganglioside by human neuroblastomaInternational Journal of Cancer, 1987